Shane McInerney

Research Programs

Neuroscience Research Program

Recent Publications

1. Wang, S, Kennedy, SH, Salomons, TV, Ceniti, AK, McInerney, SJ, Bergmans, Y et al.. Resting-state neural mechanisms of capability for suicide and their interaction with pain - A CAN-BIND-05 Study. J Affect Disord. 2023;330 :139-147. doi: 10.1016/j.jad.2023.02.147. PubMed PMID:36878406 .
2. Melia, R, Francis, K, Duggan, J, Bogue, J, O'Sullivan, M, Young, K et al.. Using a Safety Planning Mobile App to Address Suicidality in Young People Attending Community Mental Health Services in Ireland: Protocol for a Pilot Randomized Controlled Trial. JMIR Res Protoc. 2023;12 :e44205. doi: 10.2196/44205. PubMed PMID:36809171 PubMed Central PMC9993232.
3. Hicks, O, McInerney, SJ, Lam, RW, Milev, RV, Frey, BN, Soares, CN et al.. Acute and chronic stress predict anti-depressant treatment outcome and naturalistic course of major depression: A CAN-BIND report. J Affect Disord. 2022;313 :8-14. doi: 10.1016/j.jad.2022.06.058. PubMed PMID:35760190 .
4. Tourjman, SV, Buck, G, Jutras-Aswad, D, Khullar, A, McInerney, S, Saraf, G et al.. Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: A Systematic Review and Recommendations of Cannabis use in Bipolar Disorder and Major Depressive Disorder. Can J Psychiatry. 2023;68 (5):299-311. doi: 10.1177/07067437221099769. PubMed PMID:35711159 PubMed Central PMC10192829.
5. Rnic, K, Jung, YE, Torres, I, Chakrabarty, T, LeMoult, J, Vaccarino, AL et al.. Association between discrepancy in objective and subjective cognitive abilities and treatment response in patients with major depressive disorder: A CAN-BIND-1 study report. J Affect Disord. 2021;295 :1095-1101. doi: 10.1016/j.jad.2021.09.002. PubMed PMID:34706420 .
6. Melia, R, Monahan, L, Duggan, J, Bogue, J, O'Sullivan, M, Young, K et al.. Exploring the experiences of mental health professionals engaged in the adoption of mobile health technology in Irish mental health services. BMC Psychiatry. 2021;21 (1):412. doi: 10.1186/s12888-021-03426-5. PubMed PMID:34412601 PubMed Central PMC8375610.
7. Morton, E, Bhat, V, Giacobbe, P, Lou, W, Michalak, EE, McInerney, S et al.. Predictors of Quality of Life Improvement with Escitalopram and Adjunctive Aripiprazole in Patients with Major Depressive Disorder: A CAN-BIND Study Report. CNS Drugs. 2021;35 (4):439-450. doi: 10.1007/s40263-021-00803-2. PubMed PMID:33860922 .
8. Glynn, K, McKenna, F, Lally, K, O'Donnell, M, Grover, S, Chakrabarti, S et al.. How do delirium motor subtypes differ in phenomenology and contributory aetiology? a cross-sectional, multisite study of liaison psychiatry and palliative care patients. BMJ Open. 2021;11 (4):e041214. doi: 10.1136/bmjopen-2020-041214. PubMed PMID:33853791 PubMed Central PMC8054089.
9. Chakrabarty, T, McInerney, SJ, Torres, IJ, Frey, BN, Milev, RV, Müller, DJ et al.. Cognitive Outcomes with Sequential Escitalopram Monotherapy and Adjunctive Aripiprazole Treatment in Major Depressive Disorder: A Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report. CNS Drugs. 2021;35 (3):291-304. doi: 10.1007/s40263-021-00793-1. PubMed PMID:33683582 .
10. Rybak, YE, Lai, KSP, Ramasubbu, R, Vila-Rodriguez, F, Blumberger, DM, Chan, P et al.. Treatment-resistant major depressive disorder: Canadian expert consensus on definition and assessment. Depress Anxiety. 2021;38 (4):456-467. doi: 10.1002/da.23135. PubMed PMID:33528865 PubMed Central PMC8049072.